Lindsay Lally1, Lindsy Forbess2, Christopher Hatzis3, Robert Spiera3. 1. Hospital for Special Surgery, New York, New York. lally1@hss.edu. 2. Cedars-Sinai Medical Center, Los Angeles, California. 3. Hospital for Special Surgery, New York, New York.
Abstract
OBJECTIVE: Interleukin-6 (IL-6) is a pivotal cytokine in the pathogenesis of polymyalgia rheumatica (PMR), yet the efficacy of IL-6 blockade with tocilizumab (TCZ) for the treatment of PMR is unknown. The aim of this study was to assess the efficacy and safety of TCZ in newly diagnosed PMR. METHODS: In a single-center open-label study, patients with newly diagnosed PMR who had been treated with glucocorticoids (GCs) for <1 month were treated monthly with intravenous (IV) TCZ 8 mg/kg for 1 year, with a rapid tapering of GCs according to standardized protocol. The primary end point was the proportion of patients in relapse-free remission without GC treatment at 6 months. Secondary outcome measures included duration of GC use and cumulative GC dose. Patients were followed up for 15 months. RESULTS: Ten patients were enrolled in the study. One patient withdrew after 2 months, leaving 9 patients in whom the primary end point was assessed. The primary end point of relapse-free remission without GC treatment at 6 months was achieved by all 9 of these patients. All patients who received TCZ treatment were able to discontinue GCs within 4 months of study entry. The cumulative mean ± SD prednisone dose was 1,085 ± 301 mg and the total duration of GC exposure was 3.9 ± 0.9 months. Remission persisted without relapse, in all 9 patients, throughout the entire 15-month study. CONCLUSION: Our findings suggest that TCZ may be an effective, safe, and well-tolerated treatment for newly diagnosed patients with PMR, with a robust steroid-sparing effect.
OBJECTIVE:Interleukin-6 (IL-6) is a pivotal cytokine in the pathogenesis of polymyalgia rheumatica (PMR), yet the efficacy of IL-6 blockade with tocilizumab (TCZ) for the treatment of PMR is unknown. The aim of this study was to assess the efficacy and safety of TCZ in newly diagnosed PMR. METHODS: In a single-center open-label study, patients with newly diagnosed PMR who had been treated with glucocorticoids (GCs) for <1 month were treated monthly with intravenous (IV) TCZ 8 mg/kg for 1 year, with a rapid tapering of GCs according to standardized protocol. The primary end point was the proportion of patients in relapse-free remission without GC treatment at 6 months. Secondary outcome measures included duration of GC use and cumulative GC dose. Patients were followed up for 15 months. RESULTS: Ten patients were enrolled in the study. One patient withdrew after 2 months, leaving 9 patients in whom the primary end point was assessed. The primary end point of relapse-free remission without GC treatment at 6 months was achieved by all 9 of these patients. All patients who received TCZ treatment were able to discontinue GCs within 4 months of study entry. The cumulative mean ± SD prednisone dose was 1,085 ± 301 mg and the total duration of GC exposure was 3.9 ± 0.9 months. Remission persisted without relapse, in all 9 patients, throughout the entire 15-month study. CONCLUSION: Our findings suggest that TCZ may be an effective, safe, and well-tolerated treatment for newly diagnosed patients with PMR, with a robust steroid-sparing effect.
Authors: S Unizony; L Arias-Urdaneta; E Miloslavsky; S Arvikar; A Khosroshahi; B Keroack; J R Stone; J H Stone Journal: Arthritis Care Res (Hoboken) Date: 2012-11 Impact factor: 4.794
Authors: Carlo Salvarani; Fabrizio Cantini; Laura Niccoli; Pierluigi Macchioni; Dario Consonni; Gianluigi Bajocchi; Marco Vinceti; Maria Grazia Catanoso; Lia Pulsatelli; Riccardo Meliconi; Luigi Boiardi Journal: Arthritis Rheum Date: 2005-02-15
Authors: Carlo Salvarani; PierLuigi Macchioni; Carlo Manzini; Giuseppe Paolazzi; Aldo Trotta; Paolo Manganelli; Marco Cimmino; Roberto Gerli; Maria Grazia Catanoso; Luigi Boiardi; Fabrizio Cantini; Catherine Klersy; Gene G Hunder Journal: Ann Intern Med Date: 2007-05-01 Impact factor: 25.391
Authors: Roberto Caporali; Marco A Cimmino; Gianfranco Ferraccioli; Roberto Gerli; Catherine Klersy; Carlo Salvarani; Carlomaurizio Montecucco Journal: Ann Intern Med Date: 2004-10-05 Impact factor: 25.391
Authors: M J van der Veen; H J Dinant; C van Booma-Frankfort; G A van Albada-Kuipers; J W Bijlsma Journal: Ann Rheum Dis Date: 1996-04 Impact factor: 19.103
Authors: F Buttgereit; T Brabant; H Dinges; I Hiemer; M Kaplani; U Kiltz; D Kyburz; A Reißhauer; M Schneider; C Weseloh; C Dejaco Journal: Z Rheumatol Date: 2018-06 Impact factor: 1.372
Authors: Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta Journal: Nat Rev Rheumatol Date: 2017-09-14 Impact factor: 20.543